Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 14.04.2026. Verfasst von Ting-Sha He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Claudins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Arteannuin B (Art B), a sesquiterpene lactone from Artemisia annua , combats non‐small cell lung cancer (NSCLC) chemoresistance by activating a novel miR‐194‐3p/CLDN2 axis, as identified here through integrated transcriptomic and functional analyses. Here, we combined transcriptomic profiling with functional validation to identify claudin‐2 (CLDN2) as a critical mediator of Art B's anticancer effects in NSCLC. CLDN2 , significantly upregulated in NSCLC tissues versus paired normal tissues, promoted tumor cell proliferation and cisplatin resistance by upregulating multidrug resistance‐associated protein 2 (MRP2). Mechanistically, miR‐194‐3p directly binds to two conserved sites (nt 358–365 and 1232–1238) within the CLDN2 3′ UTR, suppressing its expression via mRNA degradation and translational inhibition, thereby attenuating proliferation and resensitizing cells to cisplatin. Importantly, Art B exerted antitumor effects by upregulating miR‐194‐3p , which subsequently inhibited CLDN2 . This study not only elucidates a previously unrecognized mechanism for overcoming chemoresistance but also nominates CLDN2 as a prognostic biomarker, offering a promising therapeutic strategy that could benefit NSCLC patients facing treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.
- Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou, China.
- Department of Chinese Materia Medica, College of Pharmacy, Jinan University, Guangzhou, China.
ORCID-Profile: Rong-Min Yu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
He, T. S., Chen, R. H., Feng, J., Zhang, Q., Li, X. L., Han, J. H., Chen, T. Z., Yu, R. M., Song, L. Y., & Huang, W. J. (2026). Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71796
Vancouver
He TS, Chen RH, Feng J, Zhang Q, Li XL, Han JH, et al. Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71796
BibTeX
@article{He2026,
author = {He, Ting-Sha and Chen, Rong-Hui and Feng, Jing and Zhang, Qiang and Li, Xin-Ling and Han, Jia-Hui and Chen, Tian-Ze and Yu, Rong-Min and Song, Li-Yan and Huang, Wei-Juan},
title = {Arteannuin B Inhibits NSCLC Cells via Regulating miR ‐194‐3p/ CLDN2 Axis},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71796}
}
EUVIMED